Clinical trials: Pregnancy, Multiple
Gestational Diabetes
Impact of Blood Glucose at the First Trimester of Pregnant Women With Gestational Diabetes on Maternal and Fetal Outcomes and Metabolic Disorders: a Multi-central Prospective Cohort Study
The study is to investigate the impact of blood glucose management at the first trimester of pregnant women with gestational diabetes on the maternal and fetal outcomes and metabolic disorder.
- Trial name
- NCT01833559
- Testing
- Dietary control, Insulin
- Where
- China
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Overactive Bladder
A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks
The purpose of this study is to evaluate the rate of "add-on" solifenacin treatment and its persistency in men with over active bladder symptoms after tamsulosin monotherapy for 4 weeks.
- Trial name
- NCT00884104
- Testing
- Solifenacin
- Where
- 9 sites in South Korea
- Volunteers
- 307 people
- Sponsor
- KYU-SUNG LEE
Ovarian Neoplasms, Pancreatic Neoplasms
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
The purpose of this study is to determine the recommended dose of siltuximab monotherapy, in participants with solid malignant (cancerous) tumors (a mass in a specific area) and to estimate the clinical benefit of siltuximab…
- Conditions
- Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT00841191
- Testing
- CNTO 328; Anti-interleukin-6 monoclonal antibody
- Where
- 12 sites in United States, Belgium and 3 more
- Volunteers
- 84 people
- Sponsor
- Centocor, Inc.
Down Syndrome, Fetal Aneuploidy
Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies
Whole blood samples will be collected from high-risk pregnant women to validate the clinical performance of the SEQureDx Trisomy 21 Test.
- Trial name
- NCT01555346
- Where
- 29 sites in United States, Canada
- Volunteers
- 3,062 people
- Sponsor
- Sequenom, Inc.
Diabetic Nephropathy
A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria
The purpose of this study is to evaluate pharmacodynamics, safety, tolerability and pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects with Albuminuria
- Trial name
- NCT01756703
- Testing
- MT-3995 Low, MT-3995 High
- Where
- 43 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 67 people
- Sponsor
- Tanabe Pharma Corporation
Septic Shock, Abdominal Sepsis
OXiris for Abdominal SEptic Shock (OASES Study)
This study innovatively utilizes multi-modal hemodynamic monitoring (Norepinephrine equivalence, NEE+Pulse indicator Continuous Cariac output, PiCCO) to investigate the optimal timing of initiation of oXiris in abdominal…
- Conditions
- Septic Shock, Abdominal Sepsis, Multi Organ Failure, Blood Purification
- Trial name
- OASES (NCT06504316)
- Testing
- CRRT filter
- Where
- China
- Volunteers
- 192 people
- Sponsor
- RenJi Hospital
Pregnancy, Malaria
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
There are few safe, effective, and affordable interventions to improve pregnancy outcomes in low resource settings where the highest rates of poor birth outcomes occur.
- Conditions
- Pregnancy, Malaria, Nutrition, Placental Development
- Trial name
- AGREE (NCT05934318)
- Testing
- L-citrulline
- Where
- Kenya
- Volunteers
- 2,960 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Polycystic Kidney, Autosomal Dominant
Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD
Polycystic kidney disease (ADPKD) is a common genetic disorder, characterized by the formation of cysts in the kidneys, causing gradual renal function-loss.
- Trial name
- POLY (NCT03803124)
- Testing
- Tolvaptan
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Regional Hospital Holstebro
Bacterial Vaginosis
Lcr35® for Bacterial Vaginosis Prevention
This is a national, multi-centre, randomized, double-blind placebo-controlled, phase III superiority trial. The main objective of the trial is to assess the efficacy of Lcr35® by comparing the mean time before the onset of the…
- Trial name
- NCT01160796
- Testing
- Lcr35®
- Where
- France
- Volunteers
- 352 people
- Sponsor
- Laboratoires Lyocentre
Prematurity
Coached, Coordinated, Enhanced Neonatal Transition (CCENT)
This study will evaluate a new neonatal follow-up model that offers additional support and coping resources for parents during their child's NICU admission as well as during their transition home.
- Trial name
- CCENT (NCT03350243)
- Testing
- CCENT Intervention
- Where
- 7 sites in Canada
- Volunteers
- 275 people
- Sponsor
- The Hospital for Sick Children
Cervical Cancer, Lymphocyst
A Trial Comparing Observation With Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer
Cervical cancer of early stage is treated mainly by radical resection and (or) radiotherapy. And pelvic lymphocyst is one of the most common adverse events of radical resection.
- Conditions
- Cervical Cancer, Lymphocyst, Radiation Therapy
- Trial name
- NCT03071289
- Testing
- Radiation Method B, Cisplatin, Radiation Method A
- Where
- 8 sites in China
- Volunteers
- 540 people
- Sponsor
- Sun Yat-sen University
Group B Streptococcal Infection
Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV
A randomised, placebo-controlled, double-blind study to evaluate the safety, tolerability and immunogenicity of the GBS-NN/NN2 (Recombinant protein vaccine against Group B Streptococcus) vaccine in women living with HIV and women…
- Trial name
- NCT04596878
- Testing
- GBS-NN/NN2
- Where
- 3 sites in South Africa, Uganda
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Minervax ApS
Solid Tumor, Lymphoma
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
This is a single arm Phase 2 study of the combination of adenoviral p53 (Ad-p53) gene therapy administered intra-tumorally with approved immune checkpoint inhibitors in patients with recurrent or metastatic cancers.
- Trial name
- NCT03544723
- Testing
- Ad-p53
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- MultiVir, Inc.
Leukodystrophy, White Matter Disease
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Leukodystrophies, and other heritable disorders of the white matter of the brain, were previously resistant to genetic characterization, largely due to the extreme genetic heterogeneity of molecular causes.
- Conditions
- Leukodystrophy, White Matter Disease, 4H Syndrome, Adrenoleukodystrophy
- Trial name
- NCT02699190
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Children's Hospital of Philadelphia
Overactive Bladder
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.
- Trial name
- NCT03902080
- Testing
- Vibegron
- Where
- 140 sites in United States, Belgium and 6 more
- Volunteers
- 1,105 people
- Sponsor
- Urovant Sciences GmbH
Multiple Sclerosis
Safety of Exposure to Natalizumab During Pregnancy
Multiple sclerosis (MS) preferentially affects young adults with a female predominance. MS is not associated with an increased risk of complications or abnormal pregnancy outcomes.
- Trial name
- BABYZUMAB-2 (NCT05209815)
- Testing
- Questionnaire
- Where
- 27 sites in France, Martinique
- Volunteers
- 68 people
- Sponsor
- University Hospital, Bordeaux
Breast Cancer, Lung Cancer
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used…
- Conditions
- Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer
- Trial name
- NCT05974150
- Testing
- Web based survey
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Carevive Systems, Inc.
Ovarian Cancer, High Grade Ovarian Serous
Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer
The researchers are doing this study to find out whether the researchers can combine information provided by PET/MRI scans with information from tests on blood and tissue samples to develop a very detailed description (profile)…
- Trial name
- NCT04454450
- Testing
- PET/MRI, Contrast enhanced CT
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer, Cervical Cancer
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma
- Trial name
- NCT05973487
- Testing
- TSC-204-A0201, TSC-204-C0702, TSC-200-A0201
- Where
- 21 sites in United States
- Volunteers
- 840 people
- Sponsor
- TScan Therapeutics, Inc.
Carcinoma, Renal Cell
Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
The purpose of this study is to determine how effective and safe a new investigational drug is in treating patients with relapsed or refractory multiple myeloma. The treatment involves daily dosing.
- Trial name
- NCT00256880
- Testing
- GW786034
- Where
- 8 sites in United States, Australia
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline